General LMS Research Highlights
Curated publications, research updates, clinical trials, and educational links relevant to the broader sarcoma community.
NLMSF Research Grants
2026–2027 Research Grant Announcement
LOI deadline: April 15, 2025
The National Leiomyosarcoma Foundation (NLMSF) invites letters of intent (LOIs) for pilot studies to launch new research trajectories in LMS, with a focus on basic and translational science. Clinical interventional trials are out of scope.
- Total award: $50,000 per year for 2 years (indirects ≤ 10%).
- Scope includes biomarkers, imaging, computational biology, radiomics, and lab‑based translational studies.
- Human sample studies require IRB approval (or waiver) prior to award.
Submission contacts: matthew.hemming@umassmemorial.org and alessandra.maleddu@cuanschutz.edu
Research Updates
Identification of a novel minor-groove DNA binder that represses mitochondrial gene expression and induces apoptosis in highly aggressive leiomyosarcoma cells
New research article (PubMed).
Stereotactic radiosurgery outcomes for brain metastases from sarcoma primaries (2025)
International multicenter analysis; Cancer (2025).
Leiomyosarcoma: Therapeutic approaches and future directions (2025)
Hematology/Oncology Clinics of North America.
Trabectedin + Olaparib Phase II trial in advanced sarcoma (2025)
Clin Cancer Res. Online ahead of print.
For additional items, see our News Tracker and Clinical Trials pages.
Arginine & Immunotherapy Research
Understanding Arginine Metabolism in Cancer
Exploring the potential of arginine in treating sarcoma
To explore the potential of arginine in treating sarcoma, consider the following insights. This is educational information only — always discuss any supplement or dietary change with your oncology care team.
- Arginine is an amino acid that may enhance immune function and support cancer treatment.
- Recent studies suggest that arginine can inhibit tumor growth in certain sarcoma types.
- It may improve the efficacy of chemotherapy by enhancing drug delivery to tumors.
- Arginine supplementation has shown promise in reducing treatment-related side effects.
- Ongoing clinical trials are investigating optimal dosing and administration methods.
- Consultation with healthcare providers is essential before starting any new treatment regimen.
AI explanation summary — topics covered
Our patient-friendly summary explains arginine metabolism, diet, immunotherapy relevance, and practical questions for your care team.
- What is Arginine
- Why does this matter in cancer?
- How do tumors use arginine?
- What are researchers trying to do?
- Why is this relevant for LMS / Sarcoma
- How could this affect immunotherapy?
- Important things patients should understand
- Why research in this area matters
- Arginine and Diet — what patients need to know
- What nutritional focus is important for patients to be mindful of
- Protein sources that are generally considered helpful
- Anti-inflammatory foods, healthy fats, high-fiber foods
- Foods patients often ask about regarding arginine
- What should patients avoid?
- Important considerations, areas of research being studied, and bottom line for patients
Arginine metabolism and cancer therapy strategies
In this review, researchers integrate and analyze how tumor cells and immune cells such as T cells respond to arginine, and strategies for cancer therapy. Frontiers in Oncology.
Triple pre-surgery therapy may boost immunity against soft tissue sarcoma
Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with the experimental immune-boosting drug BO-112 and anti-PD-1 therapy before surgery may help the immune system fight aggressive soft tissue sarcomas.
Findings published in Cancer Discovery show that the approach can reshape the tumor microenvironment to activate the body's immune cells against cancer.
Denise Heady, University of California, Los Angeles — edited by Sadie Harley, reviewed by Andrew Zinin
Clinical Trials & Education
Lurbinectedin + doxorubicin vs doxorubicin
Metastatic LMS — Study overview
Leiomyosarcoma — Continuing Education
NCBI Bookshelf
Therapeutic advances in leiomyosarcoma
Frontiers in Oncology
Annamycin in soft tissue sarcoma lung metastases
Phase 1b/2 MB‑107: 59.4% clinical benefit rate (n=36), median OS 13.5 months (330 mg/m²). Patients achieving response or SD after 2 cycles had median OS 19.7 months; no cardiotoxicity.
Research Library (By Year)
2025
Kourti A, Kalogiannidis I, Makedou K, Georgiou E. doi: 10.3390/ijms262210952. Full research publication available via PubMed Central.
2024
2023
2022
2021
Featured publication (2021) — A collaborative paper identifying critical gaps and priorities to accelerate progress in leiomyosarcoma research and care.
2020
2019
2018
This library highlights selections from a larger set. For the complete verbatim archive, see the section below.
Full Research Archive (Verbatim)
Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.
View full archive
The full verbatim archive includes grant announcements, key dates, and year-by-year publications (2025–2018) with links. Content is maintained by NLMSF. For the curated Research Library by year, scroll to the section above.
To add the complete HTML archive here, replace this placeholder with the full content or use the Research Library (By Year) links above for all curated items.